Chemotherapy of malignant mesothelioma
Authors:
- G. WamplerGWG. Wampler
- W. RegelsonWRW. Regelson
- D. BorochovitzDBD. Borochovitz
- T. HardyTHT. Hardy
Abstract
Twenty‐three patients with malignant mesothelioma are described as to mode of presentation, symptoms, method of diagnosis and histology. Beginning in 1972, 10 patients were treated with drug combinations including Adriamycin, Dacarbazine (DTIC), Cytoxan, and vincristine. Median survival of these patients was 9.5 months. Twelve patients who were treated with other modes of therapy had a median survival of about 4.75 months. One patient died after 22 days in the hospital, for whom a diagnosis was made at autopsy. While historical retrospective controls involving 13 patients are of limited value in assessing the usefulness of a new treatment, the authors feel that combination chemotherapy in 10 patients has shown enough activity to warrant further study. In addition, wide local resection, where possible, probably increases survival.Keywords
This publication has 8 references indexed in Scilit:
- Pleural mesotheliomaCancer, 1976
- Chemotherapy of malignant diffuse mesotheliomaCancer, 1976
- Mesothelioma following Exposure to Asbestos: A Review of 72 CasesChest, 1973
- Chemotherapy of sarcomas with a combination of adriamycin and dimethyl triazeno imidazole carboxamideCancer, 1972
- Diffuse Malignant Mesothelioma of the Pleura: A Review of 37 CasesChest, 1971
- Epidemiology of primary malignant mesothelial tumors in canadaCancer, 1970
- Histochemical demonstration of hyaluronic acid in pleural mesotheliomasThe Journal of Pathology and Bacteriology, 1962
- Fibrosarcoma. The malignant tumor of fibroblastsCancer, 1948